In a study conducted on melanoma, Ellis and co-workers demonstrated a significant reduction in the levels of cyclooxygenase (COX)-2, prostaglandin (PG) E(2), and PGE(2) receptors (EP2 and EP4) when EGCG was administered [46]. The gene discussed is PTGER4; the disease is melanoma.